Fungal Metabolite, Epoxyquinol B, Crosslinks Proteins by Epoxy-thiol Conjugation

DMSO enhances the biosynthesis of epoxyquinols in Pestalotiopsis sp. (strain IQ-011) and yields new [4 + 2] cycloaddition dimers

Pestalotiopsis sp. (strain IQ-011) produces cuautepestalorin (10), a 7,8-dihydrochromene-oxoisochromane adduct featuring a spiro-polycyclic (6/6/6/6/6/6) ring system. Additionally, it yields its proposed biosynthetic precursors: cytosporin M (1) and oxopestalochromane (11) when cultured under standard conditions (fermentation in solid media). Following an OSMAC approach guided by metabolomic studies (PCA and molecular networks), it was established that the epigenetic modulator DMSO dramatically increases the production of 1 up to 50 times according to feature-based molecular networking (FBMN) analysis, and triggers the production of other derivatives from the epoxyquinol family. Chemo-targeted isolation resulted in the discovery of four new compounds: 19-hydroxycytosporin M (2) and three [4 + 2] cycloaddition products: ent-eutyscoparol J (4), ent-pestaloquinol A (6) and ent-pestaloquinol B (8). The structures of all isolates were established based on spectroscopic, spectrometric, chiroptical, and X-ray diffraction analyses. This study demonstrates the potential of combining metabolomic tools with DMSO as an epigenetic modulator to enhance fungal metabolite diversity and highlights the importance of chiroptical methods for accurate compound identification.

Violaceoid F induces nuclear translocation of FOXO3a by inhibiting CRM1 via a novel mechanism and suppresses HeLa cell growth

FOXO3a is a transcription factor involved in cell growth inhibition and apoptosis. FOXO3a is localized in the cytoplasm in cancer cells, and its nuclear translocation by small molecules is expected to prevent cancer cell growth. In this study, we screened a fungal broth library in HeLa cells using fluorescently labeled FOXO3a and an AI-based imaging system. We identified violaceoid F, which translocates FOXO3a into the nucleus by inhibiting CRM1, which is responsible for nuclear protein export. Violaceoid F was observed to target the reactive cysteine of CRM1 through its α, β-epoxyketone. However, because violaceoid F did not inhibit Crm1 in fission yeast cells, it seems to target cysteine residue(s) other than Cys528 of human CRM1 which are not targeted by other known CRM1 inhibitors, indicating that violaceoid F inhibits CRM1 via a novel mechanism.

Targeting TAK1: Evolution of inhibitors, challenges, and future directions

The increasing incidence of inflammatory and malignant diseases signifies the need to develop first-in-class drugs with novel mechanisms of action. In this respect, the transforming growth factor (TGF)-β-activated kinase 1 (TAK1), an essential part of several signaling pathways, is considered relevant and promising. This manuscript provides a brief overview of the signal transduction orchestrated by TAK1 within these pathways, followed by an in-depth and thorough analysis of the chemical matter demonstrated to inhibit this kinase. Special attention is given to the selectivity profiling of inhibitors, as well as to the outcomes of their biological characterization. Because published TAK1 inhibitors differ significantly in their kinome selectivity, active-site binding, and biological activity, we hope that this review will allow a judicial estimation of their quality and usefulness for TAK1-addressing assays. Our thoughts on the perspectives and possible developments of the field are also provided to assist scientists who are involved in the design and development of TAK1-targeting modulators.

Natural epoxyquinoids: isolation, biological activity and synthesis. An update

Epoxyquinoids are of continuing interest due to their wide natural distribution and diverse biological activities, including, but not limited to, antibacterial, antifungal, anticancer, enzyme inhibitory, and others. The last review on their total synthesis was published in 2017. Since then, almost 100 articles have been published on their isolation from nature and their biological profile. In addition, the review specifically considers synthesis, including total and enantioselective, as well as the development of shorter approaches for the construction of epoxyquinoids with complex chemical architecture. Thus, this review focuses on progress in this area in order to stimulate further research.

Practical synthesis of ECH and epoxyquinols A and B from (-)-shikimic acid

An efficient synthesis of ECH, epoxyquinols A and B, and two bioactive analogs EqM and RKTS-33 has been completed starting from (-)-shikimic acid. Rapid establishment of the desired epoxyquinol core is facilitated through a key allylic oxidation with high stereoselectivity, which is achieved by fine tuning the cyclohexene substrate structure and reaction conditions.

Total Synthesis of (+)-Pestalofone A and (+)-Iso-A82775C

We describe the total synthesis of epoxyquinoid natural products (+)-pestalofone A and (+)-iso-A82775C. The synthesis of (+)-16-oxo-iso-A82775C, the putative biosynthetic precursor of pestalofone C, is also presented. The allene moiety present in (+)-iso-A82775C and (+)-16-oxo-iso-A82775C was constructed from the ketodiene-yne group via a biosynthetically relevant sequence involving a conjugate reduction and a base-catalyzed tautomerization. Attempted Diels-Alder reaction-based dimerizations of (+)-16-oxo-iso-A82775C and (+)-iso-A82775C toward pestalofones B and C are also described.

Epoxyquinol B, a naturally occurring pentaketide dimer, inhibits NF-kappaB signaling by crosslinking TAK1

Several epoxyquinoids interfere with NF-kappaB signaling by targeting IKKbeta or NF-kappaB. We report that epoxyquinol B (EPQB), classified as an epoxyquiniod, inhibits NF-kappaB signaling through inhibition of the TAK1 complex, a factor upstream of IKKbeta and NF-kappaB. cDNA microarray analysis revealed that EPQB decreased TNF-alpha-induced expression of NF-kappaB target genes. EPQB covalently bound to a recombinant TAK1-TAB1 fusion protein in vitro, and inhibited its kinase activity. Furthermore, in vitro/in situ treatment with EPQB resulted in a ladder-like hypershift of TAK1 protein bands. We reported recently that EPQB crosslinks proteins via cysteine residues by opening its two epoxides, and our current results suggest that EPQB inhibits NF-kappaB signaling by crosslinking TAK1 itself or TAK1 through other proteins.